Startups
Thrixen is a Singapore-based biotech company reinventing rapid point-of-care diagnostics — bioengineered Affinex® binders, a multi-domain multiplex assay and a portable reader deliver lab-quality answers wherever care happens.
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 2, 2024 | Deals in brief: IvyCap Ventures announces final close of third fund, Ion Energy raises USD 3 million, 19 China and India deals, and more | NewsDeals in brief: Xefco, Thrixen, and Salmon secure funding, Temasek invests in US-based Blaize, ten China and India deals, and more Written by Marvin Goh Xefco, Thrixen, Salmon, and more led Tuesday’s headlines: Xefco, an Australian sust... |
| Apr 30, 2024 | Thrixen secures $7m funding; Higala raises seed round; and other SE Asia deals | Thrixen, a Singapore-based healthtech startup, has announced raising $7 million in its latest funding round as it develops a diagnostics platform for infectious diseases. |
| Thrixen | “At Thrixen we are developing a diagnostic technology platform to make diagnostics available when and where they matter most. Our proprietary engineered protein binders combined with a unique assay format allow us bring essential diagnostic... |
Reviews 0
FAQ about Thrixen
What has the press written about Thrixen?
Parsers VC has collected 4 articles mentioning Thrixen, among them “Deals in brief: IvyCap Ventures announces final close of third fund, Ion Energy raises USD 3 million, 19 China and India deals, and more” (May 2, 2024) and “Thrixen secures $7m funding; Higala raises seed round; and other SE Asia deals” (Apr 30, 2024).
Is Thrixen still active?
Yes, Thrixen is active; its latest activity on Parsers VC dates from May 3, 2024.